| Drug Name |
Levomilnacipran |
| Drug ID |
BADD_D02466 |
| Description |
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor. Chemically, levomilnacipran is the 1S,2R-enantiomer of milnacipran. FDA approved on July 25, 2013. |
| Indications and Usage |
Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder (MDD). |
| Marketing Status |
approved; investigational |
| ATC Code |
N06AX28 |
| DrugBank ID |
DB08918
|
| KEGG ID |
D10072
|
| MeSH ID |
D000078862
|
| PubChem ID |
6917779
|
| TTD Drug ID |
D02XOK
|
| NDC Product Code |
65162-960; 65162-411; 65162-437; 65162-455; 68554-0115 |
| UNII |
UGM0326TXX
|
| Synonyms |
Levomilnacipran | Fetzima | Levomilnacipran Hydrochloride |
